

M KortÃ¼m

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5751074/publications.pdf>

Version: 2024-02-01

34
papers

1,212
citations

471371

17
h-index

434063

31
g-index

34
all docs

34
docs citations

34
times ranked

1788
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. <i>Blood</i> , 2016, 128, 1226-1233.	0.6	185
2	Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. <i>Nature Medicine</i> , 2021, 27, 616-619.	15.2	140
3	[⁶⁸ Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [¹⁸ F]FDG and laboratory values. <i>Theranostics</i> , 2017, 7, 205-212.	4.6	138
4	CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. <i>Theranostics</i> , 2017, 7, 1589-1597.	4.6	102
5	Spectrum and functional validation of PSMB5 mutations in multiple myeloma. <i>Leukemia</i> , 2019, 33, 447-456.	3.3	93
6	¹¹ C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. <i>Theranostics</i> , 2017, 7, 2956-2964.	4.6	63
7	CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2862-2870.	1.9	54
8	The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1248.	1.8	54
9	IKZF1/3 and CRL4 ^{CRBN} E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. <i>Haematologica</i> , 2020, 105, e237-e241.	1.7	41
10	<i>CIC</i> Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. <i>Oncologist</i> , 2020, 25, 112-118.	1.9	39
11	SnapShot: Multiple Myeloma. <i>Cancer Cell</i> , 2015, 28, 678-678.e1.	7.7	31
12	Single- and double-hit events in genes encoding immune targets before and after T cell- <i>engaging</i> antibody therapy in MM. <i>Blood Advances</i> , 2021, 5, 3794-3798.	2.5	30
13	Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease. <i>Cancers</i> , 2020, 12, 1035.	1.7	28
14	Cereblon enhancer methylation and IMiD resistance in multiple myeloma. <i>Blood</i> , 2021, 138, 1721-1726.	0.6	25
15	¹⁸ F-FDG and ¹¹ C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. <i>Cancers</i> , 2020, 12, 1042.	1.7	24
16	Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. <i>Leukemia</i> , 2022, 36, 790-800.	3.3	22
17	Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 620312.	2.2	21
18	Proteasome inhibitors block Ikaros degradation by Lenalidomide in Multiple Myeloma. <i>Haematologica</i> , 2015, 100, e315-7.	1.7	20

#	ARTICLE	IF	CITATIONS
19	18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features. <i>Cancers</i> , 2020, 12, 2333.	1.7	16
20	Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. <i>Communications Biology</i> , 2021, 4, 799.	2.0	16
21	Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model. <i>Scientific Reports</i> , 2019, 9, 18062.	1.6	14
22	⁶⁸ Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms. <i>Journal of Nuclear Medicine</i> , 2022, 63, 96-99.	2.8	13
23	Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogeneic stem cell transplantation from an EBV seronegative donor. <i>Leukemia and Lymphoma</i> , 2019, 60, 3573-3576.	0.6	10
24	Salvage therapy with daratumumab in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2022, 40, 202-211.	0.8	9
25	Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. <i>British Journal of Haematology</i> , 2022, 198, 515-522.	1.2	7
26	Protocol for M3P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma. <i>Methods in Molecular Biology</i> , 2018, 1792, 117-128.	0.4	6
27	The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT. <i>Cancers</i> , 2020, 12, 2399.	1.7	4
28	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
29	Identification of FAM46C As a Multiple Myeloma Repressor. <i>Blood</i> , 2015, 126, 836-836.	0.6	2
30	COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan. <i>Annals of Hematology</i> , 2021, 100, 843-846.	0.8	1
31	Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842098025.	1.0	1
32	M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma. <i>Blood</i> , 2015, 126, 2984-2984.	0.6	0
33	Mutations in Driver Genes and Changes in Clonal Dynamics Are Associated with Shorter Time to Treatment in MBL Cases. <i>Blood</i> , 2015, 126, 5264-5264.	0.6	0
34	CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents. <i>Leukemia and Lymphoma</i> , 0, , 1-10.	0.6	0